A study testing whether a new weekly shot, tirzepatide, can help people lose weight.

Recruiting now. Registry record last updated March 27, 2026.

Who can join: Adults 18+, have obesity, BMI 27+.
What you take: tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3.3 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Massachusetts General HospitalDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 63

What this study is for

Primary condition: Obesity.

Full scientific study title: Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have obesity, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

BMI ≥30 kg/m2 or ≥27kg/m2 with at least one weight-related medical condition
Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight
Have an established primary care provider

Key exclusion criteria

Current or prior history of diabetes mellitus based on self-report, use of diabetes medications, HbA1c ≥6.5%, or fasting glucose ≥126 mg/dL
Any single serum transaminase level (i.e., ALT, AST, alk phos) ≥3x the upper limit of normal (ULN)
Serum lipase and/or amylase levels ≥2x ULN
Serum bilirubin level \>1.6 mg/dL
Chronic kidney disease (e.g., estimated glomerular filtration rate (eGFR) \< 45 mL/min)

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Massachusetts1 site

Massachusetts General Hospital
Boston, Massachusetts
Melanie Haines, MD617-726-3870mshaines@mgh.harvard.edu

Follow this trial

We email you if NCT05933499 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: November 5, 2025. Expected completion: March 31, 2029. Last updated on ClinicalTrials.gov: March 27, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.